$1.32 Billion is the total value of ARMISTICE CAPITAL, LLC's 71 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENR | New | ENERGIZER HLDGS INC NEW | $48,220,000 | – | 1,068,000 | +100.0% | 3.66% | – |
| SRCL | New | STERICYCLE INC | $31,480,000 | – | 858,000 | +100.0% | 2.39% | – |
| WBT | New | WELBILT INC | $19,531,000 | – | 1,758,000 | +100.0% | 1.48% | – |
| SJM | New | SMUCKER J M COcall | $18,698,000 | – | 200,000 | +100.0% | 1.42% | – |
| FTDR | New | FRONTDOOR INC | $15,966,000 | – | 600,000 | +100.0% | 1.21% | – |
| TJX | New | TJX COS INC NEW | $13,422,000 | – | 300,000 | +100.0% | 1.02% | – |
| AZO | New | AUTOZONE INC | $13,413,000 | – | 16,000 | +100.0% | 1.02% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $13,125,000 | – | 1,500,000 | +100.0% | 1.00% | – |
| CVS | New | CVS HEALTH CORPcall | $13,104,000 | – | 200,000 | +100.0% | 0.99% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $12,073,000 | – | 124,000 | +100.0% | 0.92% | – |
| FL | New | FOOT LOCKER INC | $11,278,000 | – | 212,000 | +100.0% | 0.86% | – |
| PTCT | New | PTC THERAPEUTICS INC | $10,296,000 | – | 300,000 | +100.0% | 0.78% | – |
| MRKR | New | MARKER THERAPEUTICS INC | $8,258,000 | – | 1,488,000 | +100.0% | 0.63% | – |
| OLLI | New | OLLIES BARGAIN OUTLT HLDGS I | $7,183,000 | – | 108,000 | +100.0% | 0.54% | – |
| FUN | New | CEDAR FAIR L Pdepositry unit | $7,095,000 | – | 150,000 | +100.0% | 0.54% | – |
| TGT | New | TARGET CORP | $6,609,000 | – | 100,000 | +100.0% | 0.50% | – |
| AAP | New | ADVANCE AUTO PARTS INC | $6,613,000 | – | 42,000 | +100.0% | 0.50% | – |
| VLRX | New | VALERITAS HLDGS INC | $6,461,000 | – | 19,850,000 | +100.0% | 0.49% | – |
| INCY | New | INCYTE CORP | $6,359,000 | – | 100,000 | +100.0% | 0.48% | – |
| FIVE | New | FIVE BELOW INC | $6,139,000 | – | 60,000 | +100.0% | 0.46% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $5,619,000 | – | 658,000 | +100.0% | 0.43% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $4,914,000 | – | 172,000 | +100.0% | 0.37% | – |
| FLXN | New | FLEXION THERAPEUTICS INC | $4,528,000 | – | 400,000 | +100.0% | 0.34% | – |
| OVID | New | OVID THERAPEUTICS INC | $3,872,000 | – | 1,600,000 | +100.0% | 0.29% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $2,262,000 | – | 100,000 | +100.0% | 0.17% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $2,112,000 | – | 1,600,000 | +100.0% | 0.16% | – |
| MDGSW | New | MEDIGUS LTD*w exp 07/23/202 | $1,749,000 | – | 1,285,715 | +100.0% | 0.13% | – |
| ACHV | New | ACHIEVE LIFE SCIENCE INC | $542,000 | – | 448,000 | +100.0% | 0.04% | – |
| UAA | New | UNDER ARMOUR INCcl a | $530,000 | – | 30,000 | +100.0% | 0.04% | – |
| PULM | New | PULMATRIX INC | $414,000 | – | 1,723,254 | +100.0% | 0.03% | – |
| SYN | New | SYNTHETIC BIOLOGICS INC | $312,000 | – | 556,904 | +100.0% | 0.02% | – |
| CUR | New | NEURALSTEM INC | $185,000 | – | 590,000 | +100.0% | 0.01% | – |
| New | TENAX THERAPEUTICS INC | $102,000 | – | 84,590 | +100.0% | 0.01% | – | |
| AYTU | New | AYTU BIOSCIENCE INC | $79,000 | – | 100,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | 30 | Q3 2023 | 2.7% |
| SPDR S&P 500 ETF TR | 28 | Q3 2023 | 29.5% |
| MADRIGAL PHARMACEUTICALS INC | 27 | Q3 2023 | 2.9% |
| VANDA PHARMACEUTICALS INC | 26 | Q3 2021 | 9.4% |
| REGENERON PHARMACEUTICALS | 25 | Q3 2023 | 3.2% |
| ENERGIZER HLDGS INC NEW | 22 | Q2 2023 | 3.7% |
| ANTARES PHARMA INC | 21 | Q3 2020 | 6.6% |
| INCYTE CORP | 21 | Q3 2023 | 2.8% |
| VOYAGER THERAPEUTICS INC | 21 | Q3 2023 | 2.0% |
| BLUEBIRD BIO INC | 20 | Q4 2021 | 1.8% |
View ARMISTICE CAPITAL, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Avalo Therapeutics, Inc. | June 28, 2023 | 588,850 | 4.7% |
| Addex Therapeutics Ltd. | February 16, 2023 | 675,295 | 5.0% |
| Arcadia Biosciences, Inc. | February 14, 2023 | 2,675,409 | 10.0% |
| Avinger Inc | February 14, 2023 | 789,400 | 10.0% |
| Baudax Bio, Inc. | February 14, 2023 | 1,165,709 | 5.0% |
| BIORA THERAPEUTICS, INC. | February 14, 2023 | 12,989,648 | 5.7% |
| Bit Digital, Inc | February 14, 2023 | 3,161,889 | 3.7% |
| Bruush Oral Care Inc. | February 14, 2023 | 1,122,922 | 10.0% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Clarus Therapeutics Holdings, Inc. | February 14, 2023 | 2,732,169 | 5.0% |
View ARMISTICE CAPITAL, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View ARMISTICE CAPITAL, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.